Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 4;23(2):38.
doi: 10.1208/s12248-021-00559-z.

Screening of Bioequivalent Extended-Release Formulations for Metformin by Principal Component Analysis and Convolution-Based IVIVC Approach

Yufeng Zhang  1 , Hua Liu  2 , Minghui Johnson Tang  2 , Nicolas James Ho  1 , Tsun Lam Shek  1 , Zhijun Yang  3 , Zhong Zuo  4
Affiliations

Screening of Bioequivalent Extended-Release Formulations for Metformin by Principal Component Analysis and Convolution-Based IVIVC Approach

Yufeng Zhang et al. AAPS J. .

Abstract

Bioequivalence (BE) is usually hard to achieve for extended-release (ER) dosage form products due to not only its complicated formulation but also to the BCS classification of the investigated drugs. Considering the difficulties in establishing full-scale IVIVC and limited in vivo pharmacokinetics data in the early stage of formulation development, we have selected BCS III drug metformin as a model drug to demonstrate a novel approach for the selection of BE formulations. Firstly, dissolution tests in both standard and biorelevant media were performed followed by identification of the most similar formulation WM to the reference product (GXR) based on principal component analysis (PCA) of the dissolution data. Then, we developed an IVIVC model using the reported GXR pharmacokinetics profiles via a convolution-based approach. Based on our established IVIVC and in vitro dissolution profiles of generic metformin ER products, we were able to predict their in vivo pharmacokinetic profiles and quantitatively compare the differences in AUC and Cmax to ensure the correct selection of BE product. Finally, the selection of WM as the BE formulation of GXR was confirmed with a pilot BE study in healthy volunteers under fasting state. Moreover, the in vivo data from the fed state study were further integrated into our IVIVC model to identify FeSSIF-V2 as the biorelevant media for WM. Our novel integrative approach of PCA with a convolution-based IVIVC was successfully adopted for the screening of the BE metformin ER formulation and such an approach could be further utilized for the effective selection of BE formulation for other drugs/formulations with complex in vivo absorption processes.

Keywords: Glucophage XR; NONMEM; convolution-based IVIVC; dissolution; metformin extended-release tablet; time scaling.

PubMed Disclaimer

References

    1. Center for Drug Evaluation and Research. Guidance for industry: bioavailability and bioequivalence studies submitted in NDAs or INDs - General Considerations (DRAFT). US Food and Drug Administration; 2014.
    1. Center for Drug Evaluation and Research. Guidance for industry: extended release oral dosage forms: development, evaluation, and application of in vitro/in vivo correlations. US Food and Drug Administration; 1997.
    1. Le Guellec S, Ehrmann S, Vecellio L. In vitro - in vivo correlation of intranasal drug deposition. Adv Drug Deliv Rev. 2020. https://doi.org/10.1016/j.addr.2020.09.002 .
    1. Jacob S, Nair AB. An updated overview with simple and practical approach for developing in vitro-in vivo correlation. Drug Dev Res. 2018;79(3):97–110. https://doi.org/10.1002/ddr.21427 . - DOI - PubMed
    1. Kazi M, Al Amri R, Alanazi FK, Hussain MD. In vitro methods for in vitro-in vivo correlation (IVIVC) for poorly water soluble drugs: lipid based formulation perspective. Curr Drug Deliv. 2018;15(7):918–29. https://doi.org/10.2174/1567201815666180116090910 . - DOI - PubMed

Publication types

LinkOut - more resources